<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388726</article-id><article-id pub-id-type="pmc">PMC12091612</article-id>
<article-id pub-id-type="publisher-id">MD-D-25-01321</article-id><article-id pub-id-type="art-access-id">00007</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042555</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>4850</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4187-683X</contrib-id><name><surname>Bouba</surname><given-names>Yagai</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Ka&#x02019;e</surname><given-names>Aude Christelle</given-names></name><degrees>PhD</degrees><email>kae.audechristelle@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Anguechia Gouissi</surname><given-names>Davy-Hyacinthe</given-names></name><degrees>MSc</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Ayafor</surname><given-names>Cynthia</given-names></name><degrees>MSc</degrees><email>cynthia.edube@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Tameza Guebiapsi</surname><given-names>Dominik</given-names></name><degrees>MSc</degrees><email>guebiapsitameza@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Sosso</surname><given-names>Samuel Martin</given-names></name><degrees>PharmD</degrees><email>martinsosso@yahoo.it</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Simo Kamgaing</surname><given-names>Rachel</given-names></name><degrees>MD</degrees><email>kmnelly2007@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Ndiang Tetang</surname><given-names>Suzie</given-names></name><degrees>MD</degrees><email>ndiangsuzie@yahoo.fr</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Essamba</surname><given-names>Suzane</given-names></name><degrees>MD</degrees><email>suzanneessamba@yahoo.fr</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Kamgaing</surname><given-names>Nelly</given-names></name><degrees>MD</degrees><email>kmnelly2007@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Ndejo Atsinkou</surname><given-names>Sabine</given-names></name><degrees>BSc</degrees><email>atndsa2000@gmail.com</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Ketchaji</surname><given-names>Alice</given-names></name><degrees>PhD</degrees><email>ketchajialice2015@gmail.com</email><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Nka</surname><given-names>Alex Durand</given-names></name><degrees>PhD</degrees><email>nkaalexdurand@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Nguendjoung Fainguem</surname><given-names>Nadine</given-names></name><degrees>PhD</degrees><email>fainguem_dine@yahoo.fr</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Tommo Tchouaket</surname><given-names>Michel Carlos</given-names></name><degrees>PhD</degrees><email>tommomichel@yahoo.fr</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Takou</surname><given-names>Desir&#x000e9;</given-names></name><degrees>MSc</degrees><email>dtakou@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Jagni Semengue Ngoufack</surname><given-names>Ezechiel</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Amougou Atsama</surname><given-names>Marie</given-names></name><degrees>PhD</degrees><email>marieamougou164@yahoo.com</email><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Nwobegahay</surname><given-names>Julius</given-names></name><degrees>PhD</degrees><email>nwobegahay@yahoo.com</email><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Eyoum Bille</surname><given-names>Bertrand</given-names></name><degrees>PhD</degrees><email>eyoumbille@yahoo.fr</email><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Gatchuessi Kenmegne</surname><given-names>Sandra</given-names></name><degrees>MSc</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Ateba Ndongo</surname><given-names>Francis</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author"><name><surname>Noukayo</surname><given-names>Felicit&#x000e9;</given-names></name><degrees>MD</degrees><email>naahfelicy@yahoo.co.uk</email><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author"><name><surname>Awoh Ajeh</surname><given-names>Rogers</given-names></name><degrees>PhD</degrees><email>ajehrogers@gmail.com</email><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author"><name><surname>Cherif Hamsatou</surname><given-names>Hadja</given-names></name><degrees>MD</degrees><email>hamsatouhadja@cnls.cm</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Ndie</surname><given-names>Justin</given-names></name><degrees>MPH</degrees><email>ndjust2002@yahoo.fr</email><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author"><name><surname>Wepnyu Njamnshi</surname><given-names>Yembe</given-names></name><degrees>MD</degrees><email>princeyembe@gmail.com</email><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author"><name><surname>Naah</surname><given-names>Felicit&#x000e9;</given-names></name><degrees>MPH</degrees><email>naahfelicy@yahoo.co.uk</email><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author"><name><surname>Zoung-Kanyi Bissek</surname><given-names>Anne-Cecile</given-names></name><degrees>MD</degrees><email>annezkbissek@gmail.com</email><xref rid="aff13" ref-type="aff">m</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Billong</surname><given-names>Serge Clotaire</given-names></name><degrees>MD</degrees><email>sergebillong@yahoo.fr</email><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Koki Ndombo</surname><given-names>Paul</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">j</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Adawaye</surname><given-names>Chatte</given-names></name><degrees>PhD</degrees><email>adawayechatte@gmail.com</email><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author"><name><surname>Cappelli</surname><given-names>Giulia</given-names></name><degrees>PhD</degrees><email>giulia.cappelli@cnr.it</email><xref rid="aff16" ref-type="aff">p</xref><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author"><name><surname>Ekane Halle</surname><given-names>Gregory-Edie</given-names></name><degrees>MD</degrees><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author"><name><surname>Armenia</surname><given-names>Daniele</given-names></name><degrees>PhD</degrees><email>daniele.armenia@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Santoro</surname><given-names>Maria Mercedes</given-names></name><degrees>PhD</degrees><email>santormaria@gmail.com</email><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author"><name><surname>Ceccherini-Silberstein</surname><given-names>Francesca</given-names></name><degrees>PhD</degrees><email>ceccherini@med.uniroma2.it</email><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author"><name><surname>Ndembi</surname><given-names>Nicaise</given-names></name><degrees>PhD</degrees><email>nicaisen@africa-union.org</email><xref rid="aff20" ref-type="aff">t</xref><xref rid="aff21" ref-type="aff">u</xref></contrib><contrib contrib-type="author"><name><surname>Ndjolo</surname><given-names>Alexis</given-names></name><degrees>MD</degrees><email>andjolo@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Colizzi</surname><given-names>Vittorio</given-names></name><degrees>MD, PhD</degrees><email>colizzi@bio.uniroma2.it</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff17" ref-type="aff">q</xref><xref rid="aff22" ref-type="aff">v</xref></contrib><contrib contrib-type="author"><name><surname>Perno</surname><given-names>Carlo-Federico</given-names></name><degrees>MD, PhD</degrees><email>cf.perno@uniroma2.it</email><xref rid="aff23" ref-type="aff">w</xref></contrib><contrib contrib-type="author"><name><surname>Fokam</surname><given-names>Joseph</given-names></name><degrees>PhD</degrees><email>josephfokam@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff18" ref-type="aff">r</xref></contrib><aff id="aff1"><label>a</label> Departmental Faculty of Medicine and Surgery, Saint Camillus International University of Health Sciences, Rome, Italy</aff><aff id="aff2"><label>b</label> Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaound&#x000e9;, Cameroon</aff><aff id="aff3"><label>c</label> Pediatric Department, Essos Health Centre, National Social Welfare Centre, Yaound&#x000e9;, Cameroon</aff><aff id="aff4"><label>d</label> Central Technical Group, National AIDS Control Committee (NACC), Ministry of Public Health, Yaound&#x000e9;, Cameroon</aff><aff id="aff5"><label>e</label> Division of Diseases, HIV/AIDS Department, Epidemic and Pandemic Control, Ministry of Public Health, Yaound&#x000e9;, Cameroon</aff><aff id="aff6"><label>f</label> Laboratory of Virology, Research Center on Emerging and Re-Emerging Diseases (CREMER),Yaound&#x000e9;, Cameroon</aff><aff id="aff7"><label>g</label> Centre for Research and Military Health (CRESAR), Ministry of Defense, Yaound&#x000e9;, Cameroon</aff><aff id="aff8"><label>h</label> Retrovirology Laboratory, Laquintinie Hospital, Douala, Cameroon</aff><aff id="aff9"><label>i</label> Molecular Biology Laboratory, Fondation Sociale Suisse, Pette Hospital, Pette, Cameroon</aff><aff id="aff10"><label>j</label> HIV/AIDS Treatment Centre, Mother-Child Centre, Chantal BIYA Foundation, Yaound&#x000e9;, Cameroon</aff><aff id="aff11"><label>k</label> HIV/AIDS Treatment Centre, Cit&#x000e9; Verte District Hospital, Yaound&#x000e9;, Cameroon</aff><aff id="aff12"><label>l</label> Global Funds Subvention Coordination Unit, Ministry of Public Health, Yaound&#x000e9;, Cameroon</aff><aff id="aff13"><label>m</label> Division of Operational Research in Health, Ministry of Public Health, Yaound&#x000e9;, Cameroon</aff><aff id="aff14"><label>n</label> Faculty of Medicine and Biomedical Sciences, University of Yaound&#x000e9; I, Yaound&#x000e9;, Cameroon</aff><aff id="aff15"><label>o</label> Global Funds Project Management Unit, Republic of Chad, N&#x02019;djamena, Chad</aff><aff id="aff16"><label>p</label> Institute for Biological Systems (ISB), National Research Council, Rome, Italy</aff><aff id="aff17"><label>q</label> Laboratoire de Lutte contre les Grandes End&#x000e9;mies (LAGET), Centre Hospitalo-Universitaire le Bon Samaritain, N&#x02019;djamena, Chad</aff><aff id="aff18"><label>r</label> Faculty of Health Sciences, University of Buea, Buea, Cameroon</aff><aff id="aff19"><label>s</label> Department of Experimental Medicine, University of Rome &#x0201c;Tor Vergata&#x0201d;, Rome, Italy</aff><aff id="aff20"><label>t</label> Division of Surveillance and Disease Intelligence, Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia</aff><aff id="aff21"><label>u</label> Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD</aff><aff id="aff22"><label>v</label> UNESCO Board of Multidisciplinary Biotechnology, University of Rome &#x0201c;Tor Vergata&#x0201d;, Rome, Italy</aff><aff id="aff23"><label>w</label> Microbiology and Diagnostic Immunology Unit, Bambino Ges&#x000f9;&#x02019; Children Hospital, IRCCS, Rome, Italy.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Yagai Bouba, Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaound&#x000e9; 3077, Cameroon (e-mail: <email xlink:href="romeobouba@yahoo.fr">romeobouba@yahoo.fr</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42555</elocation-id><history><date date-type="received"><day>1</day><month>2</month><year>2025</year></date><date date-type="received"><day>11</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42555.pdf"/><abstract><p>Achieving and maintaining viral suppression (VS) in pediatric populations remain suboptimal in low- and middle-income countries (LMICs), calling for the optimized management approaches. We compared the rate of confirmed virological failure (cVF) and associated factors among virally non-suppressed (VnS) children and adolescents after enhanced adherence counseling (EAC) on dolutegravir-based versus other regimens. A multicentre and prospective cohort study was conducted among ART-experienced children (&#x0003c;10 years) and adolescents (10&#x02013;19 years) with VnS followed-up for confirmatory viral load (VL) after EAC. cVF was defined as 2 consecutive VL&#x02005;&#x02265;&#x02005;1000 copies/mL after &#x02265;6 months of ART and EAC. Overall, 250 individuals with VnS were enrolled, median [IQR] age was 12 (11&#x02013;13) and median duration on ART was 57 (48&#x02013;67) months. According to ART-regimens, 48.4% received DTG-based regimens (TDF/3TC/DTG: 32.8%; ABC/3TC&#x02005;+&#x02005;DTG: 15.6%). Overall, cVF rate was 39.2% (95% CI: 33.3&#x02013;45.3), with a longer duration on ART among cVF-group (68 [60&#x02013;79] months) versus VS-group (48 [45&#x02013;61]), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.026. According to ART-regimen, cVF rate was 29.3% in those receiving TDF/3TC/DTG versus 43.5% for ABC/3TC&#x02005;+&#x02005;ATV/r/LPV/r and 25.6% for ABC/3TC&#x02005;+&#x02005;DTG, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.007. Regarding anchor-drugs, cVF with DTG, EFV and ATV/r/LPV/r was 28.1%, 48.4% and 49.2%, respectively, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.007. Interestingly, 13.2% of participants with VS had detectable low-level viremia (400&#x02013;999 copies/mL), with 5.8%, 7.7% and 12.9% being observed in those receiving DTG, ATV/r/LPV/r, and EFV/NVP-based regimen, respectively, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.013. Only anchor-drug was found to be a predictor of cVF. Compared to those receiving DTG-based regimens, ART based on ATV/LPV/r (aOR [95% CI]: 0.298 [0.132&#x02013;0.72], <italic toggle="yes">P</italic>&#x02005;=&#x02005;.004) or EFV/NVP (aOR [95% CI]: 0.401 [0.163&#x02013;0.983], <italic toggle="yes">P</italic>&#x02005;=&#x02005;.046) was significantly less likely to achieve VS. About 40% of Cameroonian children/adolescents with VnS experience cVF, which is indicative that EAC significantly contributes to viral re-suppression (60%), especially with DTG-based regimens. Thus, implementing a strategy that couples DTG-transition with EAC-interventions would contribute substantially to efforts in eliminating pediatric AIDS in LMICs.</p></abstract><kwd-group><kwd>Cameroon</kwd><kwd>children and adolescents</kwd><kwd>confirmed virological failure</kwd><kwd>Dolutegravir-based regimens</kwd><kwd>enhanced adherence counseling</kwd><kwd>HIV</kwd></kwd-group><funding-group><award-group id="ID0EBUBK140435"><funding-source>IAS-CIPHER</funding-source><award-id>CIPHER-ADOLA-2023</award-id><principal-award-recipient>Yagai Bouba</principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>
1. Introduction</title><p>HIV/AIDS remains one of the major global public health challenges, especially among children and adolescents, where vulnerability and incidence remain concerning. At the end of 2022, there were an estimated total of 39.0 million people living with HIV; among them, 2.58 million and 1.65 million were children aged 0 to 10 years and 10 to 19 years, respectively.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> According to the 2022 report of the United Nations International Children&#x02019;s Emergency Fund (UNICEF), 85% of children and adolescents living with HIV were found in sub-Saharan Africa.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> In 2023, the Joint United Nations Program on HIV/AIDS (UNAIDS) recognized that the reduction of new HIV infections among children, adolescents and young people is slower when compared to adult populations. Despite the efforts to limit the spread and effects of AIDS in pediatric populations, approximately 90000 children 0 to 19 years died from AIDS-related deaths in 2023.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Globally, it is estimated that 57% of children 0 to 14 years and 65% of adolescents are not on antiretroviral treatment (ART) in 2023.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Among adolescents living with HIV in Cameroon, linkage to HIV care (including ART) was below the 95% target.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> Of all HIV-related deaths recorded nationwide in 2022, 27% occurred among children under 15 years of age, partly driven by high frequencies of virological failure observed in pediatric populations.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup></p><p>During the past years in Cameroon, first-line pediatric ART regimens were based on first-generation non-nucleoside reverse transcriptase inhibitors which are known to have a low genetic barrier to resistance, and second-line ART regimens based on protease inhibitors (PI/r). Previous studies showed that the frequencies of confirmed virological failure (cVF) among Cameroonian children and adolescents was 24% and 47% respectively, with poorer virological outcome among those on NNRTI-based regimens as compared to other regimens.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> Optimal response to ART in the pediatric population and even among people living with HIV is still of concern, due to poor adherence and emerging resistance to antiretrovirals.<sup>[<xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]</sup> Of note, almost a third of children living with HIV in Cameroon are poorly adherent to treatment, which is directly associated with virological response,<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> driven by several factors including place of living, availability of antiretroviral drugs, age, HIV status disclosure, orphanhood.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup></p><p>At a programmatic level, limited viral load (VL) coverage hinders the detection of viral non-suppression (VnS), which in turns leads to increasing (but not detected) VF and accumulation of HIV drug resistant strains reaching rates even beyond 80%.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> Consequently, the few pediatric treatment options are very limited as children grow into adolescence.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> Hence, efficient public health strategies, adapted locally, are needed for optimal selection of treatment regimens to maximize long-term ART success, reduce AIDS-related deaths and achieve the elimination targets.</p><p>World Health Organization recommends the introduction of dolutegravir (DTG)-based regimens as preferred regimen for both adult and pediatric populations, due to the increasing burden of resistance to efavirenz/nevirapine in the past years.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref>]</sup> In spite of its potency, its high genetic barrier to resistance and its forgiveness of non-adherence, the success of DTG-containing therapy requires optimal adherence monitoring as other existing ART regimens to achieve epidemic control.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> In several studies, including the ODYSSEY and IMPAACT P1093 trials, the efficacy of DTG has been proven in adults, adolescents and children living with HIV/AIDS,<sup>[<xref rid="R19" ref-type="bibr">19</xref>&#x02013;<xref rid="R26" ref-type="bibr">26</xref>]</sup> calling for regimen rollout.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup></p><p>The current transition to DTG-based regimens among children and adolescents (pDTG) in low- and middle-income countries (LMICs), including Cameroon deserves a closer assessment of its efficacy in controlling viral replication among children/adolescents using real-life adherence intervention strategies. In this context, recent studies in Cameroon showed that the frequency of virological failure are estimated at 74.4% to 88.2% in adolescents and 64.8% in children.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> However, these previous observations did not consider neither a thorough adherence assessment nor the effect of a real-life adherence intervention on the virological outcome of pediatric regimens. Such assessment is paramount in closing the knowledge gaps as countries are transitioning to pediatric DTG regimens in LMICs.<sup>[<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>]</sup></p><p>Our study objective was to compare the rate of confirmed virological failure (cVF) among virally unsuppressed children and adolescents on DTG-based versus other regimens after enhanced adherence counseling (EAC) intervention.</p></sec><sec sec-type="methods"><title>
2. Materials and methods</title><sec><title>
2.1. Study design and inclusion criteria</title><p>We conducted a comparative, multicentre and prospective cohort study among ART-experienced but virally non-suppressed children (&#x0003c;10 years) and adolescents (10&#x02013;19 years) receiving DTG-based versus other ART regimens in 6 regions of Cameroon. Participants were enrolled in the study based on living with HIV and aged less than 20 years; available information on gender and ART regimens; having a first HIV-RNA VL result in VL&#x02005;&#x02265;&#x02005;1000 copies/mL; have undergone 3 to 6 months EAC intervention; and have a second HIV-RNA VL result as the final study outcome. Any child or adolescent was excluded in case of missing data, inconsistent data; transfer-out of treatment site; ongoing co-infection with viral hepatitis; or undergoing an aggressive medical intervention (chemotherapy, transplantation, hemodialysis, etc). All the participants who fulfilled the inclusion criteria and accepted to participate were exhaustively enrolled for follow-up.</p></sec><sec><title>
2.2. Study setting</title><p>This study was conducted in Cameroon, a central African country which is one of the Global Funds and PEPFAR priority country for AIDS. Cameroon has a mixed epidemiology, with a prevalence of about 2.7% where the elimination of vertical transmission has not yet been achieved.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> For this study, participants were enrolled from treatment centers (both rural and urban) in 6 out of the 10 regions of Cameroon (Far nord, center, East, Nord, Littoral, and Adamaoua regions). The Littoral and center regions in particular are cosmopolitan cities with the highest active file of people living with HIV/AIDS in Cameroon. The laboratory data were collected from the reference laboratories operating in these regions.</p></sec><sec sec-type="methods"><title>
2.3. Study procedures</title><sec><title>
2.3.1. Enrolment</title><p>Within the national ART program, children and adolescents living with HIV and registered in recognized treatment centers constituted the study source population. Patients were enrolled from September 20, 2023, to November 12, 2024, and then followed prospectively for viral suppression (VS) after EAC-interventions. EAC was provided by health care providers at the treatment centers for 3 to 6 months, depending on the level of adherence of the participants.</p><p>Trained investigators were in charge of distributing and explaining the study&#x02019;s information sheet in French and English (since Cameroon is bilingual) to the parents or guardians. All the parents or guardians who accepted the participation of their children provided a written parental consent. In addition, all the adolescents aged from 12 years and above signed an assent form that had been validated by the ethics committee. Following enrollment, the population was then stratified into 4 groups: children&#x02005;&#x0003c;&#x02005;5 years; children 5 to 9 years; adolescents 10 to 14 years; adolescents 15 to 19 years. The socio-demographic, treatment, and other clinical parameters were collected on a standard data collection sheet using specific identifiers for confidentiality and privacy purposes.</p></sec><sec><title>
2.3.2. Viral Load measurement</title><p>For each participant, whole blood sample was collected in EDTA tubes by trained healthcare workers, centrifuged and plasma specimens aliquoted at various collection sites (spokes), stored in cold chain (&#x02013;20&#x000b0;C or &#x02013;80&#x000b0;C) and then shipped to the reference laboratory in-country for plasma VL analysis. Briefly, plasma samples extracted, RNA was reverse-transcribed and then amplified using a Real-Time PCR as per the manufacturer&#x02019;s instructions: Gene Expert point-of-care technology of Cepheid (limit of detection, LoD&#x02005;&#x0003c;&#x02005;40 copies/mL); Abbott Real-Time m2000 system (LoD&#x02005;&#x0003c;&#x02005;40 copies/mL); and open platform of Biocentric (LoD&#x02005;&#x0003c;&#x02005;390 copies/mL).</p></sec><sec><title>
2.3.3. Operational definitions and variables</title><p>The main outcome variable in this study was VS. VS was interpreted as HIV-RNA measurement&#x02005;&#x0003c;&#x02005;1000 copies/mL after at least 6 months of ART initiation (i.e. WHO guidelines for LMICs). To ensure homogeneity in VL result interpretation across RT-PCR systems with varying LoD, low-level viremia was defined as a VL between 400 and 999 copies/mL; high-level viremia as VL&#x02005;&#x02265;&#x02005;10,000 copies/mL; and cVF as 2 consecutive VL&#x02005;&#x02265;&#x02005;1000 copies/mL. The explanatory variables included the socio-demographic data (age and sex) and clinical data (treatment duration, ART treatment line, types of regimen, anchor drugs and NRTI-backbone). According to the national HIV prevention and treatment guidelines of Cameroon, patients receiving an ART based on efavirenz-, nevirapine- or dolutegravir-based regimens are part of the first-line regimens, meanwhile those receiving a PI-based regimen based on atazanavir or lopinavir are considered to be on second-line regimen. All the other combinations, including the third line regimen which is based on darunavir, were grouped as others. Participants were selected based on the exposure to EAC-interventions. Data sources include the patients medical files at the treatment centers and the database of the reference laboratories.</p></sec></sec><sec><title>
2.4. Statistical analysis</title><p>All the data (socio-demographic, clinical, ART history and 2 consecutive VLs) were centralized at the National AIDS Control Committee; data cleaning and double-checking were performed for quality control. Data were then imported from Microsoft Excel 2019 into SPSS version 26 (SPSS Inc., Chicago). Basic socio-demographic and clinical data were summarized as proportions using tables. The proportions among the various categories of the variables of interest were compared using the Chi-square test for trend, Fisher Exact test or Mann&#x02013;Witney test, as appropriate. Binary logistic regression model was used to identify factors independently associated with VS. To minimize bias, only variables with significant a <italic toggle="yes">P</italic>-values&#x02005;&#x0003c;&#x02005;.1 in the univariate analysis were adjusted for in the final multivariate logistic regression analysis; with <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05 was considered statistically significant.</p></sec><sec><title>
2.5. Ethical considerations</title><p>This study was conducted in accordance with the principles of the Declaration of Helsinki and national regulations. This Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)-ADOLA study aims to accelerate an evidence-informed, human rights-based and integrated HIV response for children and adolescents living with and affected by HIV. This study received an ethical clearance from the Centre ethics committee (CE No. 0056 CRERSHC/2023) on March 14, 2023. All the parents or guardians signed a written parental consent form; and all adolescents aged from 12 years and above signed a written assent form, as recommended by the ethics committee. Confidentiality was ensured by using only codes and restricting access to data.</p></sec></sec><sec sec-type="results"><title>
3. Results</title><sec><title>
3.1. Population and treatment characteristics</title><p>Overall, 250 individuals (children: 38.8%; adolescents: 61.2%) were eligible for the study. The median (IQR) age was 12 (11&#x02013;13) years; most of them were females (61.2%). The proportion of females significantly increased with increasing age, with up to 71.5% in the age group 15 to 19 years (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Socio-demographic and treatment characteristics according to age categories.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Total</th><th align="center" colspan="4" rowspan="1">Age categories (yr)</th></tr><tr><th align="center" rowspan="1" colspan="1">(N&#x02005;=&#x02005;250)</th><th align="center" rowspan="1" colspan="1">&#x0003c;5<break/>20 (20.8%)</th><th align="center" rowspan="1" colspan="1">5 to 9<break/>77 (30.8%)</th><th align="center" rowspan="1" colspan="1">10 to 14<break/>62 (24.8%)</th><th align="center" rowspan="1" colspan="1">15 to 19<break/>91 (36.4%)</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Sex. n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">97 (38.8)</td><td align="center" rowspan="1" colspan="1">10 (10.3)</td><td align="center" rowspan="1" colspan="1">41 (42.3)</td><td align="center" rowspan="1" colspan="1">21 (21.60)</td><td align="center" rowspan="1" colspan="1">25 (25.80)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">153 (61.2)</td><td align="center" rowspan="1" colspan="1">10 (6.5)</td><td align="center" rowspan="1" colspan="1">36 (23.5)</td><td align="center" rowspan="1" colspan="1">41 (26.8)</td><td align="center" rowspan="1" colspan="1">66 (43.1)</td></tr><tr><td align="left" colspan="6" rowspan="1">ART-line, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1st line</td><td align="center" rowspan="1" colspan="1">152 (60.8)</td><td align="center" rowspan="1" colspan="1">8 (5.3)</td><td align="center" rowspan="1" colspan="1">56 (36.8)</td><td align="center" rowspan="1" colspan="1">37 (24.3)</td><td align="center" rowspan="1" colspan="1">51 (33.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2nd line</td><td align="center" rowspan="1" colspan="1">65 (26.0)</td><td align="center" rowspan="1" colspan="1">9 (13.8)</td><td align="center" rowspan="1" colspan="1">9 (13.8)</td><td align="center" rowspan="1" colspan="1">18 (27.7)</td><td align="center" rowspan="1" colspan="1">29 (44.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">33 (13.2)</td><td align="center" rowspan="1" colspan="1">3 (9.1)</td><td align="center" rowspan="1" colspan="1">12 (36.4)</td><td align="center" rowspan="1" colspan="1">7 (21.2)</td><td align="center" rowspan="1" colspan="1">11 (33.3)</td></tr><tr><td align="left" colspan="6" rowspan="1">Backbone, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TDF/3TC</td><td align="center" rowspan="1" colspan="1">140 (56.0)</td><td align="center" rowspan="1" colspan="1">5 (3.6)</td><td align="center" rowspan="1" colspan="1">20 (14.3)</td><td align="center" rowspan="1" colspan="1">40 (28.6)</td><td align="center" rowspan="1" colspan="1">75 (53.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ABC/3TC</td><td align="center" rowspan="1" colspan="1">75 (30.0)</td><td align="center" rowspan="1" colspan="1">12 (16.0)</td><td align="center" rowspan="1" colspan="1">45 (60.0)</td><td align="center" rowspan="1" colspan="1">14 (18.7)</td><td align="center" rowspan="1" colspan="1">4 (5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">35 (14.0)</td><td align="center" rowspan="1" colspan="1">3 (8.6)</td><td align="center" rowspan="1" colspan="1">12 (34.3)</td><td align="center" rowspan="1" colspan="1">8 (22.9)</td><td align="center" rowspan="1" colspan="1">12 (34.3)</td></tr><tr><td align="left" colspan="6" rowspan="1">Anchor-drug, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DTG (INSTI)</td><td align="center" rowspan="1" colspan="1">121 (48.4)</td><td align="center" rowspan="1" colspan="1">7 (5.8)</td><td align="center" rowspan="1" colspan="1">44 (36.4)</td><td align="center" rowspan="1" colspan="1">29 (24.0)</td><td align="center" rowspan="1" colspan="1">41 (33.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EFV/NVP (NNRTI)</td><td align="center" rowspan="1" colspan="1">31 (12.4)</td><td align="center" rowspan="1" colspan="1">1 (3.2)</td><td align="center" rowspan="1" colspan="1">12 (38.7)</td><td align="center" rowspan="1" colspan="1">8 (25.8)</td><td align="center" rowspan="1" colspan="1">10 (32.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ATV/r, LPV/r or DRV/r (PI/r)</td><td align="center" rowspan="1" colspan="1">65 (26.0)</td><td align="center" rowspan="1" colspan="1">9 (13.8)</td><td align="center" rowspan="1" colspan="1">9 (13.8)</td><td align="center" rowspan="1" colspan="1">18 (27.7)</td><td align="center" rowspan="1" colspan="1">29 (44.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">33 (13.2)</td><td align="center" rowspan="1" colspan="1">3 (9.1)</td><td align="center" rowspan="1" colspan="1">12 (36.4)</td><td align="center" rowspan="1" colspan="1">7 (21.2)</td><td align="center" rowspan="1" colspan="1">11 (33.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">ART duration, median [IQR], in months</td><td align="center" rowspan="1" colspan="1">57 (30&#x02013;92)</td><td align="center" rowspan="1" colspan="1">28 (20&#x02013;43)</td><td align="center" rowspan="1" colspan="1">58 (931&#x02013;76)</td><td align="center" rowspan="1" colspan="1">63 (33&#x02013;102)</td><td align="center" rowspan="1" colspan="1">79 (37&#x02013;131)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Abbreviations: 3TC&#x02005;=&#x02005;lamivudine, ABC&#x02005;=&#x02005;abacavir, ART&#x02005;=&#x02005;antiretroviral treatment, ATV/r&#x02005;=&#x02005;ritonavir-boosted atazanavir, AZT&#x02005;=&#x02005;zidovudine, DRV/r = ritonavir-boosted darunavir, DTG = dolutegravir, EFV&#x02005;=&#x02005;efavirenz, INSTI&#x02005;=&#x02005;integrase strand-transfer inhibitor, IQR&#x02005;=&#x02005;interquartile range, LPV/r&#x02005;=&#x02005;ritonavir-boosted lopinavir, NNRTI = non-nucleoside reverse transcriptase inhibitors, NVP = nevirapine, TDF&#x02005;=&#x02005;tenofovir disoproxil fumarate.</p></fn></table-wrap-foot></table-wrap><p>Regarding ART-regimen, all participants were treatment-experienced, with a median (IQR) duration on ART of 57 (30&#x02013;92) month years; 57.6% being on ART for more than 3 years. According to ART-regimen, 60.8% and 26.0% were on first- and second-line regimens respectively, and most patients on second-line (72.3%) were&#x02005;&#x0003e;&#x02005;10 years old (Table <xref rid="T1" ref-type="table">1</xref>). The most frequent second-line ART was ABC/3TC/ATV/r or LPV/r (9.2%).</p><p>Regarding NRTI backbones, the most frequent was TDF/3TC (56%), followed by ABC/3TC (30%). Regarding anchor drugs, most patients were on DTG-based regimens (48.4%), followed by those on PI/r-based ART (26%).</p></sec><sec><title>
3.2. Viral suppression among children and adolescents according to sex and age</title><p>The overall VS (defined as a VL&#x02005;&#x0003c;&#x02005;1000 copies/mL) was 60.8% (95% CI: 66.7&#x02013;54.7), indicating an overall poor performance in treatment response. Following stratification by sex, there were no significant difference in VS between males (57.7% [95% CI: 47.8&#x02013;67.2]) and female (62.7% [95% CI: 54.9&#x02013;70.1]), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.429.</p><p>According to age groups, VS was 64.9% (95% CI: 55.1&#x02013;73.9) among children (&#x0003c;10 years) versus 58.2% (95% CI: 50.3&#x02013;65.8) in adolescents (10&#x02013;19 years), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.285, indicating a seemingly better performance in children. No significant difference in VS was found after stratifying age groups into&#x02005;&#x0003c;&#x02005;5 years, 5 to 9 years, 10 to 14 years and 15 to 19 years (<italic toggle="yes">P</italic>&#x02005;=&#x02005;.300). Compared to children&#x02005;&#x0003c;&#x02005;5 years (80.0%), those 5 to 9 years showed a lower VS (61.0%), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.113. Furthermore, between the 2 adolescent age groups, a similar VS was observed between 10 and 14 (56.5%) versus 15 and 19 years (59.3%), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.230, indicating a similar performance in ART response throughout adolescence. However, when stratifying according to sex in each group, we observed a significant difference between males (42.9%) and females (63.4%) in the age group 10 to 14 years, Figure <xref rid="F1" ref-type="fig">1</xref>.</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Viral suppression according to age groups and sex. Error bars represent the 95% confidence interval.</p></caption><graphic xlink:href="medi-104-e42555-g001" position="float"/></fig></sec><sec><title>
3.3. Viral suppression according to treatment profiles after enhanced adherence counseling</title><p>Following EAC-interventions on all these children/adolescents with unsuppressed viremia, 60.8% achieved VS; with a significantly higher median [IQR] ART duration among those with confirmed virological failure (68 [60&#x02013;79] months), when compared to those achieving VS (48 [45&#x02013;61] months), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.026. Moreover, VS varied significantly according to ART-regimens (<italic toggle="yes">P</italic>&#x02005;=&#x02005;.007), anchor-drug (<italic toggle="yes">P</italic>&#x02005;=&#x02005;.007), and treatment line (<italic toggle="yes">P</italic>&#x02005;=&#x02005;.019). Specifically, ART regimen with the highest VS rate was ABC/3TC/DTG (74.4% [60.3&#x02013;79.7]), followed by TDF/3TC/DTG (70.7% [60.3&#x02013;79.7]). Regarding treatment line, participants on first-line ART had a significantly higher rate of VS (67.8), when compared to those on second-line treatment (50.8%), <italic toggle="yes">P</italic>&#x02005;=&#x02005;.019. Regarding anchor drugs, DTG-based ART regimens showed the highest VS rate (VS: 71.9)%; meanwhile those treated with EFV- or NVP-based regimens had a VS rate of 61.1% (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Viral suppression according to treatment profiles after EAC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Total (N&#x02005;=&#x02005;250)</th><th align="center" rowspan="1" colspan="1">Unsuppressed viremia N&#x02005;=&#x02005;98 (39.2%)</th><th align="center" rowspan="1" colspan="1">Suppressed viremia N&#x02005;=&#x02005;152 (60.8%)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ART duration in months. Median (IQR)</td><td align="center" rowspan="1" colspan="1">57 (48&#x02013;67)</td><td align="center" rowspan="1" colspan="1">68 (60&#x02013;79)</td><td align="center" rowspan="1" colspan="1">48 (45&#x02013;61)</td><td align="center" rowspan="1" colspan="1">
<bold>.026</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">ART regimen, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TDF/3TC/DTG</td><td align="center" rowspan="1" colspan="1">82 (32.8)</td><td align="center" rowspan="1" colspan="1">24 (29.3)</td><td align="center" rowspan="1" colspan="1">58 (70.7)</td><td align="center" rowspan="5" colspan="1">
<bold>.007</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TDF/3TC&#x02005;+&#x02005;EFV or NVP</td><td align="center" rowspan="1" colspan="1">18 (7.2)</td><td align="center" rowspan="1" colspan="1">7 (38.9)</td><td align="center" rowspan="1" colspan="1">11 (61.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ABC/3TC/ATV/r or LPV/r</td><td align="center" rowspan="1" colspan="1">23 (9.2)</td><td align="center" rowspan="1" colspan="1">10 (43.5)</td><td align="center" rowspan="1" colspan="1">13 (56.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ABC/3TC&#x02005;+&#x02005;DTG</td><td align="center" rowspan="1" colspan="1">39 (15.6)</td><td align="center" rowspan="1" colspan="1">10 (25.6)</td><td align="center" rowspan="1" colspan="1">29 (74.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">88 (35.2)</td><td align="center" rowspan="1" colspan="1">47 (53.4)</td><td align="center" rowspan="1" colspan="1">41 (46.6)</td></tr><tr><td align="left" colspan="5" rowspan="1">Treatment line, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1st line</td><td align="center" rowspan="1" colspan="1">152 60.8)</td><td align="center" rowspan="1" colspan="1">49 (32.2)</td><td align="center" rowspan="1" colspan="1">103 (67.8)</td><td align="center" rowspan="3" colspan="1">
<bold>.019</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2nd line</td><td align="center" rowspan="1" colspan="1">65 (26.0)</td><td align="center" rowspan="1" colspan="1">32 (49.2)</td><td align="center" rowspan="1" colspan="1">33 (50.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">33 (13.2)</td><td align="center" rowspan="1" colspan="1">17 (51.5)</td><td align="center" rowspan="1" colspan="1">16 (48.5)</td></tr><tr><td align="left" colspan="5" rowspan="1">Backbone, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TDF/3TC</td><td align="center" rowspan="1" colspan="1">140 (56.0)</td><td align="center" rowspan="1" colspan="1">51 (36.4)</td><td align="center" rowspan="1" colspan="1">89 (63.6)</td><td align="center" rowspan="3" colspan="1">0.142</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ABC/3TC</td><td align="center" rowspan="1" colspan="1">75 (30.0)</td><td align="center" rowspan="1" colspan="1">28 (37.3)</td><td align="center" rowspan="1" colspan="1">47 (62.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">35 (14.0)</td><td align="center" rowspan="1" colspan="1">19 (54.3)</td><td align="center" rowspan="1" colspan="1">16 (45.7)</td></tr><tr><td align="left" colspan="5" rowspan="1">Anchor, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DTG (INSTI)</td><td align="center" rowspan="1" colspan="1">121 (48.4)</td><td align="center" rowspan="1" colspan="1">34 (28.1)</td><td align="center" rowspan="1" colspan="1">87 (71.9)</td><td align="center" rowspan="4" colspan="1">
<bold>.007</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EFV/NVP (NNRTI)</td><td align="center" rowspan="1" colspan="1">31 (12.4)</td><td align="center" rowspan="1" colspan="1">15 (48.4)</td><td align="center" rowspan="1" colspan="1">16 (51.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ATV/r, LPV/r, or DRV/r (PI/r)</td><td align="center" rowspan="1" colspan="1">65 (26.0)</td><td align="center" rowspan="1" colspan="1">32 (49.2)</td><td align="center" rowspan="1" colspan="1">33 (50.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">33 (13.2)</td><td align="center" rowspan="1" colspan="1">17 (51.5)</td><td align="center" rowspan="1" colspan="1">16 (48.5)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Note: <italic toggle="yes">P</italic>-values were computed using Chi-square test or Mann&#x02013;Whitney <italic toggle="yes">U</italic> test. <italic toggle="yes">P</italic>-values in boldface indicate those that are statistically significant.</p></fn><fn fn-type="other"><p>Abbreviations: 3TC&#x02005;=&#x02005;lamivudine, ABC&#x02005;=&#x02005;bacavir, ART&#x02005;=&#x02005;antiretroviral treatment, ATV/r&#x02005;=&#x02005;ritonavir-boosted atazanavir, AZT&#x02005;=&#x02005;zidovudine, DRV/r = ritonavir-boosted darunavir, DTG = Dolutegravir, EAC = enhanced adherence counseling, EFV&#x02005;=&#x02005;efavirenz, LPV/r&#x02005;=&#x02005;ritonavir-boosted lopinavir, NNRTI = non-nucleoside reverse transcriptase inhibitors, NVP = nevirapine, TDF&#x02005;=&#x02005;tenofovir disoproxil fumarate.</p></fn></table-wrap-foot></table-wrap><p>Notably, among those who achieved VS, up to 13.2% (20/152) exhibited a low detectable VL between (400&#x02013;999 copies/mL). Among these, the proportions of those receiving a DTG-, EFV- or ATV/LPV/r-based regimen were 8.0%, 25.0%, and 15.2%, respectively.</p></sec><sec><title>
3.4. Predictors of viral suppression among children and adolescents following enhanced adherence counseling</title><p>In the univariate binary logistic regression model, age, ART-line, ART duration, and anchor-drug were associated with VS. After adjusting for these variables, only anchor-drug and ART-line remained independently associated with VS, with the highest performance being observed with DTG-based ART (Table <xref rid="T3" ref-type="table">3</xref>). Of note, as compared to DTG-based regimens, VS rates were significantly lower for children on ATV/r or LPV/r-based ART (aOR [95% CI]: 0.298 [0.123&#x02013;0.720], <italic toggle="yes">P</italic>&#x02005;=&#x02005;.004); similarly for those on EFV/NVP, (aOR [95% CI]: 0.401 [0.163&#x02013;0.983], <italic toggle="yes">P</italic>&#x02005;=&#x02005;.046). Similar trends in VS were also observed when comparing first-line ART to other regimens, as DTG-based ART had the greatest proportion of first-line regimens in place (see Tables <xref rid="T1" ref-type="table">1</xref> and <xref rid="T3" ref-type="table">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Determinants of viral suppression among children, adolescents and young adults.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Variables</th><th align="center" colspan="4" rowspan="1">Regression model</th></tr><tr><th align="center" colspan="2" rowspan="1">Univariate model</th><th align="center" colspan="2" rowspan="1">Adjusted model</th></tr><tr><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th><th align="center" rowspan="1" colspan="1">aOR</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-values</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Age category (yr), n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<italic toggle="yes">&#x0003c;</italic>5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;5 to 9</td><td align="center" rowspan="1" colspan="1">0.392 (0.119&#x02013;1.284)</td><td align="center" rowspan="1" colspan="1">.122</td><td align="center" rowspan="1" colspan="1">0.283 (0.077&#x02013;1.035)</td><td align="center" rowspan="1" colspan="1">.056</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;10 to 14</td><td align="center" rowspan="1" colspan="1">0.324 (0.097&#x02013;1.082)</td><td align="center" rowspan="1" colspan="1">.067</td><td align="center" rowspan="1" colspan="1">0.281 (0.073&#x02013;1.075)</td><td align="center" rowspan="1" colspan="1">.064</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;15 to 19</td><td align="center" rowspan="1" colspan="1">0.365 (0.113&#x02013;1.179)</td><td align="center" rowspan="1" colspan="1">.092</td><td align="center" rowspan="1" colspan="1">0.366 (0.097&#x02013;1.389)</td><td align="center" rowspan="1" colspan="1">.140</td></tr><tr><td align="left" colspan="5" rowspan="1">Sex, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">1.233 (0.734&#x02013;2.073)</td><td align="center" rowspan="1" colspan="1">.429</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ART duration, median (IQR), per 12-mo increase</td><td align="center" rowspan="1" colspan="1">0.931 (0.967&#x02013;0.999)</td><td align="center" rowspan="1" colspan="1">.047</td><td align="center" rowspan="1" colspan="1">0.961 (0.882&#x02013;1.046)</td><td align="center" rowspan="1" colspan="1">.356</td></tr><tr><td align="left" colspan="5" rowspan="1">Art treatment line</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1st Line</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2nd Line</td><td align="center" rowspan="1" colspan="1"><bold>0.491 (0.271&#x02013;0.888</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.019</bold>
</td><td align="center" rowspan="1" colspan="1"><bold>0.298 (0.132&#x02013;0.672</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1"><bold>0.448 (0.209&#x02013;0.960</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.039</bold>
</td><td align="center" rowspan="1" colspan="1"><bold>0.013 (0.139&#x02013;0.709</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.005</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">Anchor drug. n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DTG (INSTI)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EFV/NVP (NNRTI)</td><td align="center" rowspan="1" colspan="1"><bold>0.417 (0.186&#x02013;0.935</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.034</bold>
</td><td align="center" rowspan="1" colspan="1"><bold>0.401 (0.163&#x02013;0.983</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.046</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ATV/r or LPV/r (PI/r)</td><td align="center" rowspan="1" colspan="1"><bold>0.403 (0.215&#x02013;0.755</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.005</bold>
</td><td align="center" rowspan="1" colspan="1"><bold>0.298 (0.132&#x02013;0.720</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1"><bold>0.368 (0.167&#x02013;0.810</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.013</bold>
</td><td align="center" rowspan="1" colspan="1"><bold>0.313 (0.139&#x02013;0.709</bold>)</td><td align="center" rowspan="1" colspan="1">
<bold>.005</bold>
</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Note: The model was adjusted for age, treatment duration, ART-line and ART anchor-drug. Numbers in boldface indicate those that were significantly associated (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05) with virological suppression.</p></fn><fn fn-type="other"><p>Abbreviations: ABC = abacavir, aOR = adjusted odds ratio, ART = antiretroviral treatment lamivudine, ATV/r = ritonavir-boosted atazanavir, AZT = zidovudine, cART = combined antiretroviral therapy, CI = confidence interval, DRV/r = ritonavir-boosted darunavir, DTG = dolutegravir, EFV = efavirenz, LPV/r = ritonavir-boosted lopinavir, NNRTI = non-nucleoside reverse transcriptase inhibitors, NVP = nevirapine, OR = odds ratio, TDF = tenofovir disoproxil fumarate.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>
4. Discussion</title><p>In a context where pediatric DTG regimens are being rolled-out in LMICs (i.e. about half in Cameroon, 48.4% receiving DTG-containing ART from our study), strategies to optimize ART outcomes become relevant for supporting the global effort toward HIV elimination. Our findings among virally unsuppressed children/adolescents provide confirmatory evidence on the significance of EAC intervention when dealing with pediatrics. Of note, with about 61% VS following EAC, overall cVF was only about 39%, distributed as 35% in children and 42% in adolescents, with VS been driven by DTG-based ART while cVF has been driven by other ART regimens, owing to the suboptimal potency and lower genetic barrier to resistance especially with NNRTI-containing ART.<sup>[<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref>]</sup> This also suggests that the implementation of adherence under high genetic barrier regimens provides a greater chance of achieving VS, because of the lower chance for the virus to develop resistance in case of low adherence, compared to regimens with lower genetic barrier. We recently reported that the VS on DTG-based regimen was 85%, compared to 80.0% on efavirenz/nevirapine and 65.6% on lopinavir/ritonavir or atazanavir/ritonavir.<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> Thus, a strategy that combines enhanced pediatric DTG-transition and active adherence support will help LMICs to meet the global UNAIDS target of 95% VS by 2025.</p><p>As non-adherence to ART remains a major risk factor to cVF and drug resistance emergence,<sup>[<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R32" ref-type="bibr">32</xref>]</sup> our finding underscores the key role of implementing local adherence support strategies to further sustain the effectiveness of DTG-based regimens.<sup>[<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R33" ref-type="bibr">33</xref>]</sup> This is in line with the 2019 WHO recommendations for transitioning patients on DTG-based regimens due to their high potency and forgiveness of non-adherence.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R34" ref-type="bibr">34</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref>]</sup> In Cameroon, we previously demonstrated a slow transition rate to DTG in the pediatric population (20%), which prompted scale-up nationwide with about half of them currently benefiting from this new regimen (48.4%).<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup></p><p>According to ART-regimen, cVF rate was significantly lower (about 29%) in those receiving TDF/3TC/DTG against an alarming rate with ABC/3TC/ATV/r or LPV/r (43.5%). This underscores scaling-up transition of pediatric DTG-based regimens in Cameroon and similar settings.<sup>[<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref>]</sup></p><p>Considering the local experience in adherence support, EAC intervention consisted of psychological support, peer-mentor&#x02019;s social support groups and therapeutic sessions to discuss challenges in treatment compliance with parents and/or children/adolescents whenever appropriate. These contributed substantially to achieving good treatment outcomes as previously reported by Tanyi et al in another country,<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup> and by our group in Cameroon.<sup>[<xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R40" ref-type="bibr">40</xref>]</sup> Thus, further considerations including discrimination, stigma, equity, and shared socio-professional opportunities are measures to uptake current performance, especially with the &#x0201c;U&#x02005;=&#x02005;U&#x0201d; realities (<italic toggle="yes">undetectable viremia&#x02005;=&#x02005;untransmissible virus</italic>).<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup></p><p>The present study opens door for future interventions, including the potential introduction of long acting cabotegravir plus rilpivirine that represents an additional opportunity to improve VS. It is therefore important to provide evidence of the feasibility and field operational issues related to the use of such novel strategies during adolescence, as postulated by the ongoing CIPHER-ADOLA study. Generating such evidence would be of great importance in confirming the preserved efficacy of cabotegravir while selecting children/adolescents with minimal risks of HIV resistance to rilpivirine (second generation NNRTI sharing some cross-resistance with EFV and/or NVP), following alarming level of drug resistance reported among adolescents in Cameroon.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R41" ref-type="bibr">41</xref>]</sup></p><p>In our study, VS was independently linked to ART-regimen, as observed in studies conducted in similar settings.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R42" ref-type="bibr">42</xref>]</sup> The lack of a significant difference in VS according to sex might be due to the selection of solely patients experiencing non-VS and applying the same EAC intervention to all, regardless of sex.</p><p>Even though 2 consecutive unsuppressed VL were used to define cVF, the lack of a laboratory adherence marker (drug concentration measurement in blood, tenofovir in urine, genotypic drug resistance testing) limits the strength of our findings, since a non-negligible proportion of children/adolescents might be non-adherent even after EAC with self-reported assessment. Therefore, in the current DTG-era, innovative interventions need to be implemented to support favorable ART outcomes in LMICs further. This study has some limitations. First, as an observational study, potential biases might been introduced, but adjustments were appropriately made in statistical analyses to minimize its impact. Secondly, resistance testing was not performed among participants with confirmed virological failure in order to better characterize the reasons for failure. Other studies with more exhaustive explanatory variables are therefore warranted to overcome these limitations and confirm the generalizability of this study.</p></sec><sec><title>
5. Conclusion</title><p>In LMICs transitioning to DTG-containing regimens, ART adherence remains a cornerstone to achieve treatment success. In real-life setting like Cameroon where unsuppressed viremia is common, only about 40% of virally unsuppressed children/adolescents would experience cVF after EAC, indicating that EAC contributes significantly to viral re-suppression (60%), especially with DTG-based regimens. Thus, implementing a strategy that couples DTG-transition with EAC intervention would contribute substantially to efforts in eliminating pediatric AIDS in LMICs.</p></sec><sec><title>Acknowledgments</title><p>We are very appreciative of all health care workers in the HIV treatment centers and HIV reference laboratories who contributed to the clinical follow-up and the viral load tests. We also acknowledge the collaboration of regional coordinators of the participating regions to ensuring supervision, data collection and processing at the central level. We thank all the children/adolescents and their parents who provided data for this study.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Yagai Bouba, Aude Christelle Ka'e, Nelly Kamgaing, Hadja Cherif Hamsatou, Anne-Cecile Zoung-Kanyi Bissek, Serge Clotaire Billong, Gregory-Edie Ekane Halle, Daniele Armenia, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Nicaise Ndembi, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Data curation:</bold> Yagai Bouba, Aude Christelle Ka'e, Davy-Hyacinthe Anguechia Gouissi, Cynthia Ayafor, Dominik Tameza Guebiapsi, Samuel Martin Sosso, Suzie Ndiang Tetang, Suzane Essamba, Sabine Ndejo Atsinkou, Alex Durand Nka, Nadine Nguendjoung Fainguem, Michel Carlos Tommo Tchouaket, Desir&#x000e9; Takou, Ezechiel Jagni Semengue Ngoufack, Marie Amougou Atsama, Julius Nwobegahay, Bertrand Eyoum Bille, Sandra Gatchuessi Kenmegne, Francis Ateba Ndongo, Joseph Fokam.</p><p><bold>Formal analysis:</bold> Yagai Bouba, Aude Christelle Ka'e, Davy-Hyacinthe Anguechia Gouissi, Dominik Tameza Guebiapsi, Alex Durand Nka, Michel Carlos Tommo Tchouaket, Ezechiel Jagni Semengue Ngoufack, Francis Ateba Ndongo, Daniele Armenia, Joseph Fokam.</p><p><bold>Funding acquisition:</bold> Yagai Bouba, Anne-Cecile Zoung-Kanyi Bissek, Serge Clotaire Billong, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Nicaise Ndembi, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Investigation:</bold> Aude Christelle Ka'e, Davy-Hyacinthe Anguechia Gouissi, Cynthia Ayafor, Dominik Tameza Guebiapsi, Samuel Martin Sosso, Rachel Simo Kamgaing, Suzie Ndiang Tetang, Suzane Essamba, Sabine Ndejo Atsinkou, Alex Durand Nka, Nadine Nguendjoung Fainguem, Michel Carlos Tommo Tchouaket, Desir&#x000e9; Takou, Ezechiel Jagni Semengue Ngoufack, Marie Amougou Atsama, Julius Nwobegahay, Bertrand Eyoum Bille, Sandra Gatchuessi Kenmegne, Francis Ateba Ndongo, Felicit&#x000e9; Noukayo, Felicit&#x000e9; Naah, Joseph Fokam.</p><p><bold>Methodology:</bold> Yagai Bouba, Aude Christelle Ka'e, Davy-Hyacinthe Anguechia Gouissi, Cynthia Ayafor, Rachel Simo Kamgaing, Suzie Ndiang Tetang, Suzane Essamba, Nelly Kamgaing, Sabine Ndejo Atsinkou, Alice Ketchaji, Alex Durand Nka, Nadine Nguendjoung Fainguem, Michel Carlos Tommo Tchouaket, Desir&#x000e9; Takou, Ezechiel Jagni Semengue Ngoufack, Marie Amougou Atsama, Julius Nwobegahay, Bertrand Eyoum Bille, Sandra Gatchuessi Kenmegne, Francis Ateba Ndongo, Felicit&#x000e9; Noukayo, Hadja Cherif Hamsatou, Justin Ndie, Yembe Wepnyu Njamnshi, Felicit&#x000e9; Naah, Serge Clotaire Billong, Chatte Adawaye, Giulia Cappelli, Gregory-Edie Ekane Halle, Daniele Armenia, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Nicaise Ndembi, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Project administration:</bold> Yagai Bouba, Desir&#x000e9; Takou, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Resources:</bold> Rogers Awoh Ajeh, Hadja Cherif Hamsatou, Anne-Cecile Zoung-Kanyi Bissek, Gregory-Edie Ekane Halle, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Supervision:</bold> Samuel Martin Sosso, Rachel Simo Kamgaing, Suzie Ndiang Tetang, Nelly Kamgaing, Julius Nwobegahay, Sandra Gatchuessi Kenmegne, Felicit&#x000e9; Noukayo, Rogers Awoh Ajeh, Hadja Cherif Hamsatou, Yembe Wepnyu Njamnshi, Anne-Cecile Zoung-Kanyi Bissek, Serge Clotaire Billong, Paul Koki Ndombo, Daniele Armenia, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Nicaise Ndembi, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Validation:</bold> Samuel Martin Sosso, Nelly Kamgaing, Alice Ketchaji, Julius Nwobegahay, Rogers Awoh Ajeh, Yembe Wepnyu Njamnshi, Anne-Cecile Zoung-Kanyi Bissek, Serge Clotaire Billong, Paul Koki Ndombo, Chatte Adawaye, Giulia Cappelli, Gregory-Edie Ekane Halle, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Nicaise Ndembi, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam.</p><p><bold>Visualization:</bold> Yagai Bouba, Aude Christelle Ka'e, Cynthia Ayafor, Dominik Tameza Guebiapsi, Rachel Simo Kamgaing, Suzane Essamba, Nelly Kamgaing, Sabine Ndejo Atsinkou, Alice Ketchaji, Alex Durand Nka, Nadine Nguendjoung Fainguem, Michel Carlos Tommo Tchouaket, Justin Ndie, Nicaise Ndembi, Joseph Fokam.</p><p><bold>Writing &#x02013; original draft:</bold> Yagai Bouba, Aude Christelle Ka'e, Davy-Hyacinthe Anguechia Gouissi, Dominik Tameza Guebiapsi, Suzie Ndiang Tetang, Alex Durand Nka, Nadine Nguendjoung Fainguem, Michel Carlos Tommo Tchouaket, Desir&#x000e9; Takou, Ezechiel Jagni Semengue Ngoufack, Marie Amougou Atsama, Bertrand Eyoum Bille, Joseph Fokam.</p><p><bold>Writing &#x02013; review &#x00026; editing:</bold> Nelly Kamgaing, Alice Ketchaji, Francis Ateba Ndongo, Rogers Awoh Ajeh, Justin Ndie, Yembe Wepnyu Njamnshi, Felicit&#x000e9; Naah, Anne-Cecile Zoung-Kanyi Bissek, Serge Clotaire Billong, Paul Koki Ndombo, Chatte Adawaye, Giulia Cappelli, Gregory-Edie Ekane Halle, Daniele Armenia, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Nicaise Ndembi, Alexis Ndjolo, Vittorio Colizzi, Carlo-Federico Perno.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>3TC</term><def><p>lamivudine</p></def></def-item><def-item><term>ABC</term><def><p>abacavir</p></def></def-item><def-item><term>AIDS</term><def><p>acquired immunodeficiency syndrome</p></def></def-item><def-item><term>ART</term><def><p>antiretroviral therapy</p></def></def-item><def-item><term>ATV</term><def><p>atazanavir</p></def></def-item><def-item><term>cART</term><def><p>combination antiretroviral therapy</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CIRCB</term><def><p>Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management</p></def></def-item><def-item><term>cVF</term><def><p>confirmed virological failure</p></def></def-item><def-item><term>DTG</term><def><p>dolutegravir</p></def></def-item><def-item><term>EAC</term><def><p>enhanced adherence counseling</p></def></def-item><def-item><term>EFV</term><def><p>efavirenz</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>HIVDR</term><def><p>HIV drug resistance</p></def></def-item><def-item><term>IQR</term><def><p>interquartile range</p></def></def-item><def-item><term>LMICs</term><def><p>low- and middle-income countries</p></def></def-item><def-item><term>LPV</term><def><p>lopinavir</p></def></def-item><def-item><term>NNRTI</term><def><p>non-nucleoside reverse transcriptase</p></def></def-item><def-item><term>NVP</term><def><p>nevirapine</p></def></def-item><def-item><term>PI/r</term><def><p>protease inhibitors boosted with ritonavir</p></def></def-item><def-item><term>SSA</term><def><p>Sub-Saharan Africa</p></def></def-item><def-item><term>TDF</term><def><p>tenofovir disoproxil fumarate</p></def></def-item><def-item><term>UNAIDS</term><def><p>Joint United Nations Programme on HIV/AIDS</p></def></def-item><def-item><term>UNICEF</term><def><p>United Nations International Children&#x02019;s Emergency Fund</p></def></def-item><def-item><term>VF</term><def><p>virological failure</p></def></def-item><def-item><term>VL</term><def><p>viral load</p></def></def-item><def-item><term>VnS</term><def><p>viral non-suppression</p></def></def-item><def-item><term>VS</term><def><p>viral suppression</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organisation</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This research was funded by the International AIDS Society through the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER-ADOLA-2023), and partly supported by PETVISIDAME (2CMR 1017) within the framework of the 2023 PMTCT forum in Cameroon. The funders had no role in the design, data collection, analyses and interpretation of the results presented in this manuscript.</p></fn><fn fn-type="other"><p>The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the regional delegation of public health for the Centre region of Cameroon (CE No 0056 CRERSHC/2023) on March 14, 2023.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Bouba Y, Ka&#x02019;e AC, Anguechia Gouissi D-H, Ayafor C, Tameza Guebiapsi D, Sosso SM, Simo Kamgaing R, Ndiang Tetang S, Essamba S, Kamgaing N, Ndejo Atsinkou S, Ketchaji A, Nka AD, Nguendjoung Fainguem N, Tommo Tchouaket MC, Takou D, Jagni Semengue Ngoufack E, Amougou Atsama M, Nwobegahay J, Eyoum Bille B, Gatchuessi Kenmegne S, Ateba Ndongo F, Noukayo F, Awoh Ajeh R, Cherif Hamsatou H, Ndie J, Wepnyu Njamnshi Y, Naah F, Zoung-Kanyi Bissek A-C, Billong SC, Koki Ndombo P, Adawaye C, Cappelli G, Ekane Halle G-E, Armenia D, Santoro MM, Ceccherini-Silberstein F, Ndembi N, Ndjolo A, Colizzi V, Perno C-F, Fokam J. Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon. Medicine 2025;104:20(e42555).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>. <article-title>HIV/AIDS fact sheet</article-title>
<year>2021</year>. <comment>Available at: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/hiv-aids" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/hiv-aids</ext-link>. Accessed January 30, 2025</comment>.</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="book"><collab>UNAIDS</collab>. <article-title>FACT SHEET 2021 global HIV statistics.</article-title>
<source>Ending the AIDS epidemic</source>. <year>2021</year>;<fpage>1</fpage>-<lpage>3</lpage>. <comment>Available at: <ext-link xlink:href="https://www.unaids.org/en/resources/fact-sheet" ext-link-type="uri">https://www.unaids.org/en/resources/fact-sheet</ext-link>. Accessed October 30, 2024</comment>.</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><collab>UNICEF</collab>. <article-title>Adolescent HIV treatment &#x02013; July 2023 Update.</article-title>
<comment>Available at: <ext-link xlink:href="https://data.unicef.org/topic/hivaids/adolescent-hiv-treatment/" ext-link-type="uri">https://data.unicef.org/topic/hivaids/adolescent-hiv-treatment/</ext-link>. Accessed January 30, 2025</comment>.</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><collab>National AIDS Control Committee (NACC), Cameroon Ministry of Public Health</collab>. <comment>Annual Report 2023. Available at: <ext-link xlink:href="https://www.cnls.cm/uploads/docs/2025-01-02-rapport-annuel-2023-vih-draft-final-latest.pdf" ext-link-type="uri">https://www.cnls.cm/uploads/docs/2025-01-02-rapport-annuel-2023-vih-draft-final-latest.pdf</ext-link>. Accessed April 11, 2025</comment>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Sosso</surname><given-names>SM</given-names></name><name><surname>Yagai</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of &#x0201c;test and treat.&#x0201d;.</article-title>
<source>AIDS Res Ther</source>. <year>2019</year>;<volume>16</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">31744517</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koay</surname><given-names>WLA</given-names></name><name><surname>Kose-Otieno</surname><given-names>J</given-names></name><name><surname>Rakhmanina</surname><given-names>N</given-names></name></person-group>. <article-title>HIV drug resistance in children and adolescents: always a challenge?</article-title>
<source>Curr Epidemiol Rep</source>. <year>2021</year>;<volume>8</volume>:<fpage>97</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">33758743</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salou</surname><given-names>M</given-names></name><name><surname>Dagnra</surname><given-names>AY</given-names></name><name><surname>Butel</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>High rates of virological failure and drug resistance in perinatally HIV&#x02010;1&#x02010;infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.</article-title>
<source>J Int AIDS Soc</source>. <year>2016</year>;<volume>19</volume>:<fpage>20683</fpage>.<pub-id pub-id-type="pmid">27125320</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantino</surname><given-names>N</given-names></name><name><surname>Lowery</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>LK</given-names></name></person-group>. <article-title>Adherence to HIV care and associated health functioning among youth living with HIV in Sub-Saharan Africa.</article-title>
<source>AIDS Rev</source>. <year>2021</year>;<volume>22</volume>:<fpage>93</fpage>&#x02013;<lpage>102</lpage>.</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Takou</surname><given-names>D</given-names></name><name><surname>Njume</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon.</article-title>
<source>HIV Med</source>. <year>2021</year>;<volume>22</volume>:<fpage>567</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">33792134</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shumetie</surname><given-names>A</given-names></name><name><surname>Moges</surname><given-names>NA</given-names></name><name><surname>Teshome</surname><given-names>M</given-names></name><name><surname>Gedif</surname><given-names>G</given-names></name></person-group>. <article-title>Determinants of virological failure among HIV-infected children on first-line antiretroviral therapy in West Gojjam Zone, Amhara Region, Ethiopia.</article-title>
<source>HIV AIDS (Auckl)</source>. <year>2021</year>;<volume>13</volume>:<fpage>1035</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">34934365</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dow</surname><given-names>DE</given-names></name><name><surname>Shayo</surname><given-names>AM</given-names></name><name><surname>Cunningham</surname><given-names>CK</given-names></name><name><surname>Mmbaga</surname><given-names>BT</given-names></name></person-group>. <article-title>HIV-1 drug resistance and virologic outcomes among tanzanian youth living with HIV.</article-title>
<source>Pediatr Infect Dis J</source>. <year>2019</year>;<volume>38</volume>:<fpage>617</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30724834</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>. <article-title>Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach.</article-title>
<comment>Available at: <ext-link xlink:href="https://www.who.int/publications/i/item/9789240031593" ext-link-type="uri">https://www.who.int/publications/i/item/9789240031593</ext-link>. Accessed October 30, 2024</comment>.</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billong</surname><given-names>SC</given-names></name><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Nkwescheu</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Early warning indicators for HIV drug resistance in cameroon during the Year 2010.</article-title>
<source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e36777</fpage>.<pub-id pub-id-type="pmid">22615810</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Santoro</surname><given-names>MM</given-names></name><name><surname>Takou</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- And second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).</article-title>
<source>BMC Pediatr</source>. <year>2019</year>;<volume>19</volume>:<fpage>226</fpage>.<pub-id pub-id-type="pmid">31277610</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntamatungiro</surname><given-names>AJ</given-names></name><name><surname>Kagura</surname><given-names>J</given-names></name><name><surname>Weisser</surname><given-names>M</given-names></name><name><surname>Francis</surname><given-names>JM</given-names></name></person-group>. <article-title>Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis.</article-title>
<source>J Antimicrob Chemother</source>. <year>2022</year>;<volume>77</volume>:<fpage>3231</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">36225089</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>F</given-names></name><name><surname>Reichmuth</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: systematic review and Bayesian evidence synthesis.</article-title>
<source>J Clin Epidemiol</source>. <year>2022</year>;<volume>148</volume>:<fpage>135</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">35192922</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Nka</surname><given-names>AD</given-names></name><name><surname>Dzukam</surname><given-names>FYM</given-names></name><etal/></person-group>. <article-title>Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: children at high risk of virological failure due to the lowly transition in pediatrics.</article-title>
<source>Medicine (Baltimore)</source>. <year>2023</year>;<volume>102</volume>:<fpage>e33737</fpage>.<pub-id pub-id-type="pmid">37335723</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djiyou</surname><given-names>ABD</given-names></name><name><surname>Penda</surname><given-names>CI</given-names></name><name><surname>Madec</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target.</article-title>
<source>BMC Pediatr</source>. <year>2023</year>;<volume>23</volume>:<fpage>119</fpage>.<pub-id pub-id-type="pmid">36922769</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viani</surname><given-names>RM</given-names></name><name><surname>Ruel</surname><given-names>T</given-names></name><name><surname>Alvero</surname><given-names>C</given-names></name><etal/></person-group>; <collab>P1093 Study Team</collab> . <article-title>Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the impaact P1093 study.</article-title>
<source>J. Pediatric Infect. Dis. Soc</source>. <year>2020</year>;<volume>9</volume>:<fpage>159</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">30951600</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollen</surname><given-names>PDJ</given-names></name><name><surname>Moore</surname><given-names>CL</given-names></name><name><surname>Mujuru</surname><given-names>HA</given-names></name><etal/></person-group>; <collab>ODYSSEY trial team</collab>. <article-title>Simplified dolutegravir dosing for children with HIV weighing 20&#x02009;kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.</article-title>
<source>Lancet HIV</source>. <year>2020</year>;<volume>7</volume>:<fpage>e533</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">32763217</pub-id>
</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waalewijn</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>MK</given-names></name><name><surname>Bollen</surname><given-names>PDJ</given-names></name><etal/></person-group>; <collab>ODYSSEY Trial Team</collab>. <article-title>Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.</article-title>
<source>Lancet HIV</source>. <year>2022</year>;<volume>9</volume>:<fpage>e341</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">35189082</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>S</given-names></name><name><surname>Berenguer</surname><given-names>J</given-names></name></person-group>. <article-title>Efficacy of dolutegravir in treatment-experienced patients: The SAILING and VIKING trials.</article-title>
<source>Enferm Infecc Microbiol Clin</source>. <year>2015</year>;<volume>33</volume>:<fpage>26</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">25858609</pub-id>
</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>van Lunzen</surname><given-names>J</given-names></name><etal/></person-group>; <collab>FLAMINGO study team</collab>. <article-title>Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.</article-title>
<source>Lancet HIV</source>. <year>2015</year>;<volume>2</volume>:<fpage>e127</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">26424673</pub-id>
</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboud</surname><given-names>M</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Lombaard</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.</article-title>
<source>Lancet Infect Dis</source>. <year>2019</year>;<volume>19</volume>:<fpage>253</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30732940</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raffi</surname><given-names>F</given-names></name><name><surname>Jaeger</surname><given-names>H</given-names></name><name><surname>Quiros-Roldan</surname><given-names>E</given-names></name><etal/></person-group>; <collab>extended SPRING-2 Study Group</collab>. <article-title>Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.</article-title>
<source>Lancet Infect Dis</source>. <year>2013</year>;<volume>13</volume>:<fpage>927</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">24074642</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armenia</surname><given-names>D</given-names></name><name><surname>Bouba</surname><given-names>Y</given-names></name><name><surname>Gagliardini</surname><given-names>R</given-names></name><etal/></person-group>; <collab>Italian INI-Surveillance Group</collab>. <article-title>Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.</article-title>
<source>J Clin Virol</source>. <year>2020</year>;<volume>130</volume>:<fpage>104534</fpage>.<pub-id pub-id-type="pmid">32769022</pub-id>
</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biney</surname><given-names>IJK</given-names></name><name><surname>Kyei</surname><given-names>KA</given-names></name><name><surname>Ganu</surname><given-names>VJ</given-names></name><etal/></person-group>. <article-title>Antiretroviral therapy adherence and viral suppression among HIV-infected adolescents and young adults at a tertiary hospital in Ghana.</article-title>
<source>African J AIDS Res</source>. <year>2021</year>;<volume>20</volume>:<fpage>270</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buh</surname><given-names>A</given-names></name><name><surname>Deonandan</surname><given-names>R</given-names></name><name><surname>Gomes</surname><given-names>J</given-names></name><name><surname>Krentel</surname><given-names>A</given-names></name><name><surname>Oladimeji</surname><given-names>O</given-names></name><name><surname>Yaya</surname><given-names>S</given-names></name></person-group>. <article-title>Barriers and facilitators to ART adherence among ART non-adherence people living with HIV in cameroon: a qualitative phenomenological study.</article-title>
<source>PLoS One</source>. <year>2023</year>;<volume>18</volume>:<fpage>e0291487</fpage>.<pub-id pub-id-type="pmid">37699048</pub-id>
</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semengue</surname><given-names>ENJ</given-names></name><name><surname>Santoro</surname><given-names>MM</given-names></name><name><surname>Ndze</surname><given-names>VN</given-names></name><etal/></person-group>. <article-title>HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis.</article-title>
<source>PLOS Global Public Health</source>. <year>2022</year>;<volume>2</volume>:<fpage>e0000826</fpage>.<pub-id pub-id-type="pmid">36962573</pub-id>
</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Chenwi</surname><given-names>CA</given-names></name><name><surname>Tala</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Pre-treatment HIV drug resistance and genetic diversity in cameroon: implications for first-line regimens.</article-title>
<source>Viruses</source>. <year>2023</year>;<volume>15</volume>:<fpage>1458</fpage>.<pub-id pub-id-type="pmid">37515146</pub-id>
</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Bouba</surname><given-names>Y</given-names></name><name><surname>Ajeh</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Evaluation of viral suppression in paediatric populations: implications for the transition to dolutegravir-based regimens in cameroon: the CIPHER-ADOLA study.</article-title>
<source>Biomedicines</source>. <year>2024</year>;<volume>12</volume>:<fpage>2083</fpage>.<pub-id pub-id-type="pmid">39335597</pub-id>
</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Elat</surname><given-names>JBN</given-names></name><name><surname>Billong</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Monitoring HIV drug resistance early warning indicators in Cameroon: a study following the revised world health organization recommendations.</article-title>
<source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0129210</fpage>.<pub-id pub-id-type="pmid">26083364</pub-id>
</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villiera</surname><given-names>JB</given-names></name><name><surname>Katsabola</surname><given-names>H</given-names></name><name><surname>Bvumbwe</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Factors associated with antiretroviral therapy adherence among adolescents living with HIV in the era of isoniazid preventive therapy as part of HIV care.</article-title>
<source>PLOS Global Public Health</source>. <year>2022</year>;<volume>2</volume>:<fpage>e0000418</fpage>.<pub-id pub-id-type="pmid">36962329</pub-id>
</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruzzese</surname><given-names>E</given-names></name><name><surname>Lo Vecchio</surname><given-names>A</given-names></name><name><surname>Smarrazzo</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric patients.</article-title>
<source>Ital J Pediatr</source>. <year>2018</year>;<volume>44</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">29558972</pub-id>
</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semengue</surname><given-names>ENJ</given-names></name><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Etame</surname><given-names>NK</given-names></name><etal/></person-group>. <article-title>Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-LINE ART in Cameroon: an evidence of a successful transition model.</article-title>
<source>Viruses</source>. <year>2022</year>;<volume>15</volume>:<fpage>18</fpage>.<pub-id pub-id-type="pmid">36680058</pub-id>
</mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psichogiou</surname><given-names>M</given-names></name><name><surname>Poulakou</surname><given-names>G</given-names></name><name><surname>Basoulis</surname><given-names>D</given-names></name><name><surname>Paraskevis</surname><given-names>D</given-names></name><name><surname>Markogiannakis</surname><given-names>A</given-names></name><name><surname>Daikos</surname><given-names>GL</given-names></name></person-group>. <article-title>Recent advances in antiretroviral agents: potent integrase inhibitors.</article-title>
<source>Curr Pharm Des</source>. <year>2017</year>;<volume>23</volume>:<fpage>2552</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">28356041</pub-id>
</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathbun</surname><given-names>RC</given-names></name><name><surname>Lockhart</surname><given-names>SM</given-names></name><name><surname>Miller</surname><given-names>MM</given-names></name><name><surname>Liedtke</surname><given-names>MD</given-names></name></person-group>. <article-title>Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.</article-title>
<source>Ann Pharmacother</source>. <year>2014</year>;<volume>48</volume>:<fpage>395</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">24259658</pub-id>
</mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanyi</surname><given-names>NW</given-names></name><name><surname>Gachuno</surname><given-names>O</given-names></name><name><surname>Odero</surname><given-names>T</given-names></name><name><surname>Farquhar</surname><given-names>C</given-names></name><name><surname>Kimosop</surname><given-names>D</given-names></name><name><surname>Mayi</surname><given-names>A</given-names></name></person-group>. <article-title>Factors affecting adherence to antiretroviral therapy among children and adolescents living with HIV in the Mbita Sub County Hospital, Homa Bay&#x02013; Kenya.</article-title>
<source>Afr Health Sci</source>. <year>2021</year>;<volume>21</volume>:<fpage>18</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">34447419</pub-id>
</mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ida Penda</surname><given-names>C</given-names></name><name><surname>Zoung-Kanyi Bissek</surname><given-names>AC</given-names></name><name><surname>Clotaire Bilong</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Impact of therapeutic education on the viral load of HIV infected children and adolescents on antiretroviral therapy at the Douala Laquintinie Hospital, Cameroon.</article-title>
<source>Int J Clin Med</source>. <year>2016</year>;<volume>10</volume>:<fpage>109</fpage>&#x02013;<lpage>21</lpage>.</mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mb&#x000e9;bi Enon&#x000e9;</surname><given-names>PJ</given-names></name><name><surname>Penda</surname><given-names>CI</given-names></name><name><surname>Ngondi</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>High risk of virologic failure among HIV-infected children and adolescents routinely followed-up in Littoral region of Cameroon.</article-title>
<source>PLoS One</source>. <year>2023</year>;<volume>18</volume>:<fpage>e0289426</fpage>.<pub-id pub-id-type="pmid">37561800</pub-id>
</mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kityo</surname><given-names>C</given-names></name><name><surname>Mambule</surname><given-names>IK</given-names></name><name><surname>Musaazi</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.</article-title>
<source>Lancet Infect Dis</source>. <year>2024</year>;<volume>24</volume>:<fpage>1083</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">38821073</pub-id>
</mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okonji</surname><given-names>EF</given-names></name><name><surname>van Wyk</surname><given-names>B</given-names></name><name><surname>Mukumbang</surname><given-names>FC</given-names></name><name><surname>Hughes</surname><given-names>GD</given-names></name></person-group>. <article-title>Determinants of viral suppression among adolescents on antiretroviral treatment in Ehlanzeni district, South Africa: a cross-sectional analysis.</article-title>
<source>AIDS Res Ther</source>. <year>2021</year>;<volume>18</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33407664</pub-id>
</mixed-citation></ref></ref-list></back></article>